Celgene Corp. (CELG)

102.00
1.00 1.00
NASDAQ : Health Technology
Prev Close 100.97
Open 101.11
Day Low/High 101.11 / 102.02
52 Wk Low/High 58.59 / 101.22
Volume 2.09M
Avg Volume 3.59M
Exchange NASDAQ
Shares Outstanding 708.74M
Market Cap 71.55B
EPS 5.70
P/E Ratio 13.83
Div & Yield N.A. (N.A)

Latest News

Don't Wait for China: Cramer's 'Mad Money' Recap (Friday 9/20/19)

Don't Wait for China: Cramer's 'Mad Money' Recap (Friday 9/20/19)

Jim Cramer says it's going to take longer than most people think to reach a trade deal with China. He's got your game plan for next week.

Celgene Corporation Names Second Round Of Celgene Cancer Care Links™ Program Grant Recipients

Celgene Corporation Names Second Round Of Celgene Cancer Care Links™ Program Grant Recipients

Celgene Corporation (NASDAQ: CELG) today announced an additional ten programs selected for funding under its Celgene Cancer Care Links™ program, an initiative designed to support healthcare capacity building in resource-constrained countries around the...

Celgene Announces Phase 3 QUAZAR® AML-001 Study Of CC-486 As Maintenance Therapy In Patients With Newly Diagnosed Acute Myeloid Leukemia Met Primary And Key Secondary Endpoints

Celgene Announces Phase 3 QUAZAR® AML-001 Study Of CC-486 As Maintenance Therapy In Patients With Newly Diagnosed Acute Myeloid Leukemia Met Primary And Key Secondary Endpoints

Celgene Corporation (NASDAQ: CELG) today announced top-line results from the international phase 3, randomized, double-blind, placebo-controlled study, QUAZAR AML-001.

Jim Cramer: How to Survive This Violent Rotation

Jim Cramer: How to Survive This Violent Rotation

Emotions and panic must be checked at the door, if you are going to be a successful investor, especially right now.

Data From Ozanimod Clinical Development Program In Relapsing Forms Of Multiple Sclerosis To Be Presented At The 35th Congress Of The European Committee For Treatment And Research In Multiple Sclerosis

Data From Ozanimod Clinical Development Program In Relapsing Forms Of Multiple Sclerosis To Be Presented At The 35th Congress Of The European Committee For Treatment And Research In Multiple Sclerosis

Celgene Corporation (NASDAQ:CELG) today announced it will present 13 scientific abstracts, including new analyses from the Phase 3 ozanimod clinical development program in adults with relapsing forms of multiple sclerosis (RMS), at the 35 th Congress of...

Stocks End Higher After Trump Says China Wants to Make a Deal 'Very Badly'

Stocks End Higher After Trump Says China Wants to Make a Deal 'Very Badly'

Stocks finished higher Monday after President Donald Trump claims China contacted U.S. trade officials and said 'let's get back to' the negotiating table.

Jim Cramer: Why It Doesn't Matter How Much Amgen Paid for Otzela

Jim Cramer: Why It Doesn't Matter How Much Amgen Paid for Otzela

Jim Cramer breaks down Amgen's deal to buy Otezla's rights from Celgene.

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.

Alexion Shares Decline in Wake of Amgen's Deal for Otezla

Alexion Shares Decline in Wake of Amgen's Deal for Otezla

Recent speculation that the biotech giant would buy Alexion had boosted ALXN's shares. But Amgen just agreed to lay out $13.4 billion for Celgene's psoriasis drug.

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.

Jim Cramer Weighs In on Amgen's Deal, Salesforce and U.S.-China Trade War

Jim Cramer Weighs In on Amgen's Deal, Salesforce and U.S.-China Trade War

Jim Cramer's breaking down his thoughts on pajama trading, and the U.S.-China trade war.

Amgen Charts Indicate Shares Want to Work Their Way Higher Longer Term

Amgen Charts Indicate Shares Want to Work Their Way Higher Longer Term

Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.

Put the Pajamas Away: Jim Cramer on U.S.-China Trade and Amgen

Put the Pajamas Away: Jim Cramer on U.S.-China Trade and Amgen

Jim Cramer weighs in on the U.S.-China trade war and Amgen.

Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation

Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation

Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.

An Exit, a Purchase, and an Upgrade Monday Morning

We will sell out of one of the most expensive stocks in the portfolio (Shopify) with no yield and redeploy that capital into one of the cheapest in the portfolio with a solid yield (Viacom).

Amgen to Acquire Celgene's Otezla for $13.4 Billion in Cash

Amgen to Acquire Celgene's Otezla for $13.4 Billion in Cash

Amgen will acquire the global rights to Celgene's oral psoriasis treatment Otezla for $13.4 billion in cash, paving the way for Bristol Myers-Squibb to compete its acquisition of Celgene.

Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits

Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits

Innovative Therapy Will Strengthen Amgen's Inflammation Portfolio for Patients Around the World

Amgen and Johnson & Johnson Get a Checkup

Jefferies raises its price target for AMGN and judgement day looms for JNJ; here's our take on the health of both companies.

U.S. FDA Approves INREBIC® (Fedratinib) As First New Treatment In Nearly A Decade For Patients With Myelofibrosis

U.S. FDA Approves INREBIC® (Fedratinib) As First New Treatment In Nearly A Decade For Patients With Myelofibrosis

Celgene Corporation (NASDAQ: CELG) today announced the U.S.

Big Pharma Sees Pockets of Recent Insider Buying

Big Pharma Sees Pockets of Recent Insider Buying

AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.

Jim Cramer: 7 Sectors You Can Buy as the Trade War Continues

Jim Cramer: 7 Sectors You Can Buy as the Trade War Continues

These stocks and sectors are safe havens, and may even be opportunities.

Putting Amgen's Q2 Earnings Under the Microscope

Here we break down the numbers of some of the company's top drugs, but we now only have 175 shares remaining in this tag end of a position, as there are better health care stocks in the market right now.

Celgene Posts Strong Second-Quarter Earnings, Raises Guidance

Celgene Posts Strong Second-Quarter Earnings, Raises Guidance

Drugmaker Celgene reports second-quarter adjusted earnings and revenue that beat analysts' forecasts and raises its guidance through the remainder of the year amid strong sales of its cancer and other disease-fighting treatments.

Celgene Reports Second Quarter 2019 Operating And Financial Results

Celgene Reports Second Quarter 2019 Operating And Financial Results

Celgene Corporation (NASDAQ: CELG) reported second quarter 2019 total revenue of $4,400 million, a 15 percent increase compared to $3,814 million in the second quarter of 2018.

Bristol-Myers Squibb Announces European Commission Approval Of Pending Acquisition Of Celgene

Bristol-Myers Squibb Announces European Commission Approval Of Pending Acquisition Of Celgene

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission (EC) has granted unconditional approval of Bristol-Myers Squibb's pending acquisition of Celgene Corporation (NASDAQ:CELG).

2 Promising $5 Biotech Stocks to Consider on Recent News

2 Promising $5 Biotech Stocks to Consider on Recent News

Jounce Therapeutics and Ocular Therapeutix each provided investors with positive news morsels last week.

Jim Cramer: Add 'Better Than Feared' to Your Investing Lexicon

Jim Cramer: Add 'Better Than Feared' to Your Investing Lexicon

Here's the only way to explain why stocks jump like mad if the companies underneath them only perform slightly better than the analysts worried they would.

What to Watch for Earnings In the Second Half of 2019

What to Watch for Earnings In the Second Half of 2019

Edward Jones' Investment Strategist says Q3 and Q4 earnings season will be solid but not spectacular. Here's why.

TheStreet Quant Rating: C+ (Hold)